真人作爱免费视频,日韩在线观看免费,亚洲精品国产精品乱码不卞

Global Biopharma Layoffs June 2025 Layoffs Layoff BioNTech Gilead Biopharma layoffs surge in June 2025 as major companies like Genentech, Vertex, and Recursion downsize. Explore the latest job cuts, site closures, and restructuring trends across the industry.
Merck KGaA Lupus Drug Trial Update: Enpatoran Phase 2 Insights Merck Autoimmune Merck KGaA reveals detailed results from its phase 2 lupus trial of enpatoran, highlighting mixed outcomes in different patient cohorts and plans to pursue regulatory approval based on promising secondary endpoint data.
Insmed Advances TPIP with Phase 2b PAH Success Insmed Insmed reports strong Phase 2b results for TPIP in pulmonary arterial hypertension (PAH), showing significant efficacy and safety. The company plans to launch Phase 3 trials in PAH and PH-ILD by 2026.
Nuvation Bio's Ibtrozi Gains FDA Nod to Compete in Lung Cancer Market FDA Nuvation Bio Cancer Nuvation Bio’s Ibtrozi (taletrectinib) secures FDA approval for treating ROS1-positive non-small cell lung cancer, offering a next-gen alternative to Pfizer, BMS, and Roche therapies with strong efficacy and CNS safety.
Bristol Myers Squibb Bets on ACP3 in $1.35B Deal BMS Biotech Philochem Bristol Myers Squibb teams up with Philochem in a $1.35B radiopharma deal to develop OncoACP3, a novel prostate cancer therapy targeting ACP3, offering a potential alternative to PSMA-focused treatments.
Shanghai-Suzhou: Biopharma's Next hub? Market Trend As the global race in the biopharmaceutical industry accelerates, the Shanghai-Suzhou cluster is emerging as a powerful contender. Ranked 9th worldwide by the 2024 MedCity report, this dynamic duo from China is challenging the dominance of legacy giants like Boston, NewYork, and London.
Elevation Oncology Acquired After Ending Partnership with CSPC CSPC Elevation Oncology Elevation Oncology has been acquired by Concentra Biosciences after halting its Claudin18.2 ADC program with CSPC. The deal includes a $22M valuation and future rights tied to EO-1022, its sole remaining HER3-targeted ADC candidate.
Klotho Neurosciences Extends Lifespan by 20%, Stock Soars 788% w Klotho Neurosciences Biotech Anti-aging Klotho Neurosciences announces a breakthrough in anti-aging research, extending lifespan by 20% in mice using AAV-Klotho gene therapy. Stock price surges 788% on the news.
China Surpasses US in Clinical Trials: Leading Global Biotechnology Innovation in 2024 Market Trend Biotech China has surpassed the US in clinical trial numbers in 2024, leading global biotech innovation. Major pharma licensing, rising patents, and booming R&D hubs highlight China’s growing dominance in healthcare research.
Pfizer's Strategic Bet on Bispecifics Pfizer Akeso Pfizer commits up to $6B for rights to SSGJ-707, a PD-1xVEGF bispecific, after in-depth due diligence in China. The asset is expected to complement Pfizer’s ADC portfolio and advance its oncology strategy.